Table 7.

Guidelines for timing of waitlist placement for transplant candidates

Timing of placing a patient on the lung transplant waitlist (all patients with ILD)* Decline in FVC ≥10% during a 6-month follow-up period (a lesser degree of decline has been associated with a poorer prognosis and may call for earlier listing) Decline in DLCO ≥15% during a 6-month follow-up period Oxyhemoglobin desaturation to <88% or 6-MWT distance <250 meters or >50 meter decline in 6-MWT distance over a 6-month period

Timing of placing a patient on the lung transplant waitlist (all patients with PVD)* NYHA Functional Class III or IV symptoms despite 3 months of combination vasoactive therapies (including prostanoids) Cardiac index <2 L/min/m2 Mean right atrial pressure >15 mm Hg 6-MWT distance <350 meters Significant hemoptysis, pericardial effusion, or progressive right heart failure (as evidenced by renal dysfunction, increasing serum bilirubin, increasing serum BNP, or recurrent ascites)

Suggested timing of waitlist placement for patients with sarcoidosis Decline in FVC ≥10% during a 6-month follow-up period (a lesser degree of decline has been associated with a poorer prognosis and may call for earlier listing) Decline in DLCO ≥15% during a 6-month follow-up period Oxyhemoglobin desaturation to <88% or 6-MWT distance <250 meters or >50 meter decline in 6-MWT distance over a 6-month period NYHA Functional Class III or IV symptoms despite 3 months of combination vasoactive therapies (including prostanoids) Cardiac index <2 L/min/m2 Mean right atrial pressure >15 mm Hg 6-MWT distance <350 meters Significant hemoptysis, pericardial effusion, or progressive right heart failure (as evidenced by renal dysfunction, increasing serum bilirubin, increasing serum BNP, or recurrent ascites)